22 results for "David Hsiehchen"
Showing 1–20 · 1.17 seconds · RSS
-
Journal Article Full text
The Cooperative Landscape of Multinational Clinical Trials.
The scale and nature of cooperative efforts spanning geopolitical borders in clinical research have not been elucidated to date. In a cross-sectional study of 110,428 interventional trials registered in Clinicaltrials.gov, we characterized the evolution, trial demographics, and network properties…
Also available at: PLOS
-
Journal Article
Female dermatology journal editors accepting pharmaceutical payments: An analysis of the Open Payments database, 2013 to 2018
Background: Pharmaceutical payments may affect the interpretation of clinical research and prescribing patterns of physicians. Additionally, they may reflect gender disparities in academic dermatology with regard to social recognition and opportunities for career advancement. Objective: We examined…
-
Journal Article
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
Background Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of pseudo-stability/progression after atezolizumab…
-
Journal Article
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial
Abstract T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes and NK cells, and is a candidate compensatory immune checkpoint that may mediate anti-PD-1/L1 resistance in hepatocellular carcinoma (HCC). We conducted the phase 2 LIVERTI trial testing…
-
Journal Article
Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial
Abstract T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor that promotes immune evasion, and dual blockade of TIGIT and PD-1 may restore antitumor immunity. Here we report the primary analysis of the biliary tract cancer cohort from a phase 2 trial (ClinicalTrials.gov…
-
Journal Article
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
Abstract Acquired resistance to systemic treatments is inevitable in most cancers, but the genetic basis for this in many cancer types has remained elusive due to constraints in obtaining tissue specimens longitudinally. In the management of gastrointestinal cancers, molecular profiling is…
-
Journal Article
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but prediction of their benefit is challenging. Neoantigens generated through impaired non-mismatch DNA repair may result in greater ICI activity. By analyzing 1,661 ICI-treated patients, we show that deletions and…
-
Journal Article
T-cell tolerant fraction as a predictor of immune-related adverse events
Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into the risk of irAEs. Here we evaluate a novel…
-
Journal Article
Association between immune-related adverse event timing and treatment outcomes
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE timing influences this association is unknown. We analyzed two independent cohorts…
-
Journal Article
Characteristics and clinical outcomes in young‐onset cholangiocarcinoma
Abstract Background While the incidence of cholangiocarcinoma is rising, little is known about young‐onset disease. We compared clinical characteristics and outcomes between patients with young‐onset cholangiocarcinoma, diagnosed between the ages of 18 and
-
Journal Article
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Background Increased body mass index (BMI) has been associated with improved response to immune checkpoint inhibitors (ICIs) in multiple cancer types. We evaluated associations between BMI, ICI dosing strategy, and clinical outcomes.Methods We abstracted clinical data on patients with cancer…
-
Journal Article
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial
Abstract Immune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a…
-
Journal Article
Innate and adaptive immune features associated with immune-related adverse events
Background While highly efficacious for numerous cancers, immune checkpoint inhibitors (ICIs) can cause unpredictable and potentially severe immune-related adverse events (irAEs), underscoring the need to understand irAE biology.Methods We used a multidimensional approach incorporating single-cell…
-
Journal Article
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
Abstract Polybromo-1 (PBRM1) loss of function mutations are present in a fraction of biliary tract cancers (BTCs). PBRM1, a subunit of the PBAF chromatin-remodeling complex, is involved in DNA damage repair. Herein, we aimed to decipher the molecular landscape of PBRM1 mutated (mut) BTCs and to…
-
Journal Article
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
BackgroundA useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of treatment initiation, thereby providing information…
-
Journal Article
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer
Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in Black and White patients with lung cancer. Methods: Patients scheduled to receive…